Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Price Target at $11.67

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.3333.

A number of equities research analysts have issued reports on the stock. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Cantor Fitzgerald boosted their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. Finally, Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in EPRX. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the third quarter worth approximately $7,965,000. Ally Bridge Group NY LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $5,398,000. Velan Capital Investment Management LP bought a new stake in Eupraxia Pharmaceuticals in the third quarter worth $2,077,000. Royal Bank of Canada increased its position in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Eupraxia Pharmaceuticals during the third quarter worth $1,475,000.

Eupraxia Pharmaceuticals Price Performance

NASDAQ:EPRX opened at $9.03 on Thursday. The stock has a market cap of $324.72 million, a PE ratio of -10.38 and a beta of 1.21. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $9.32. The stock’s 50-day moving average is $7.01 and its two-hundred day moving average is $6.07.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. On average, equities research analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.